. 2022 Aug 15;5(8):e2225411. doi: 10.1001/jamanetworkopen.2022.25411

Table 2. Adverse Events in the Safety Population in IV and SC Groups^a.

Adverse Event	Participants, No. (%)
	IV					SC
	Placebo	Casirivimab and imdevimab				Placebo	Casirivimab and imdevimab
	Placebo	300 mg	600 mg	1200 mg	2400 mg	Placebo	600 mg	1200 mg
No.	57	115	114	116	115	58	114	114
Patients with
Any TEAE	10 (17.5)	10 (8.7)	16 (14.0)	22 (19.0)	9 (7.8)	6 (10.3)	5 (4.4)	12 (10.5)
Any grade 3 or 4 TEAE	1 (1.8)	0	1 (0.9)	1 (0.9)	0	0	0	0
Any SAE	0	0	0	1 (0.9)	1 (0.9)	0	0	0
Any AESI	1 (1.8)	0	1 (0.9)	2 (1.7)	0	0	0	1 (0.9)
Any serious AESI	0	0	0	0	0	0	0	0
Infusion-related reaction (grade ≥2) through day 4	0	0	0	0	0	0	0	0
Injection-site reactions (grade ≥3) through day 4	0	0	0	0	0	0	0	0
Hypersensitivity reactions (grade ≥2) through day 29	0	0	0	0	0	0	0	0
Any TEAE leading to death	0	0	0	0	0	0	0	0
Any TEAE leading to withdrawal from the study medication	0	0	0	0	1 (0.9)	0	0	0
Any TEAE leading to study infusion interruption	0	0	0	0	0	0	0	0

Abbreviations: AESI, adverse event of special interest; IV, intravenous; SAE, serious adverse event; SC, subcutaneous; TEAE, treatment-emergent adverse event.

^{^a}

The safety population includes all randomized patients who received any study drug.

Table 2. Adverse Events in the Safety Population in IV and SC Groupsa.

Table 2. Adverse Events in the Safety Population in IV and SC Groups^a.